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Florida, Orlando, Florida; and 3National High Magnetic Field Laboratory, Tallahassee, FloridaABSTRACT PAP248–286 is a 39-residue fragment (residues 248 to 286) derived from protease cleavage of prostatic acidic
phosphatase in semen. The amyloid fibrils formed in vitro by PAP248–286 can dramatically enhance human immunodeficiency
virus (HIV) infection. To our knowledge, we present the first report that the HIV-enhancing potency of fibrils formed by PAP248–
286 is morphology dependent. We identified pleomorphic fibrils by transmission electron microscopy in two buffer conditions.
Our solid-state NMR data showed that these fibrils consist of molecules in distinct conformations. In agreement with NMR, fluo-
rescence measurements confirmed that they are assembled along different pathways, with distinct molecular structures.
Furthermore, our cell-based infectivity tests detected distinct HIV-enhancing potencies for fibrils in distinct morphologies. In
addition, our transmission electron microscopy and NMR results showed that semen-derived enhancer of viral infection fibrils
formed in sodium bicarbonate buffer remain stable over time, but semen-derived enhancer of viral infection fibrils formed in
phosphate buffered saline keep evolving after the initial 7 days incubation period. Given time, most of the assemblies in phos-
phate buffered saline will turn into elongated thin fibrils. They have similar secondary structure but different packing than thin
fibrils formed initially after 7 days incubation.INTRODUCTIONPredominantly, acquired immunodeficiency syndrome
(AIDS) infections are transmitted via sexual intercourse
(1). However, the efficiency of human immunodeficiency
virus (HIV) sexual transmission is surprisingly low, i.e.,
only one out of 200–2,000 coital acts results in infection
(2). In addition to the concentration of virus particles in
the ejaculates, semen itself is an important modulator of
HIV transmissibility. However, the effect of semen on
HIV infection is still debated, because it contains both
viral-enhancing (3–11) and -inhibiting factors (7,8,12,13).
Recently, a potent HIV-enhancing factor was discovered
by screening proteins in semen. PAP248–286 is the most
populated fragment derived from protease cleavage of the
prostate acidic phosphatase (PAP) (3), a protein present in
human semen at mg/mL concentration (14). At high concen-
tration, PAP248–286 assembles in vitro into amyloid fibrils
if shaken vigorously (3). These fibrils can enhance HIV up
to 100,000 times, and thus are called semen-derived
enhancer of viral infection (SEVI) (3). Such a potent modu-
lator of HIV infection can dictate the role of semen in HIV
sexual transmission.
The original in vitro fibrillization condition for SEVI
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0006-3495/15/04/2028/10 $2.00saline (PBS) buffer, which is far from any physiologically
relevant conditions. Recently, similar SEVI were shown to
form in seminal plasma (SP) at an accelerated rate without
agitation by Olsen et al. (5), due to the presence of anionic
buffer components such as sodium bicarbonate. In addition,
they also demonstrated that a high concentration of Zn2þ in
SP protects SEVI fibrils from seminal proteases (5), which
addressed concerns that SEVI fibrils, even if they do form
in semen, could be digested by protease in SP (15). More
recently, Usmani et al. (16) were able to directly identify am-
yloid fibrils containing PAP248–286 in semen by confocal,
transmission electron microscopy (TEM) and atomic force
microscopy (AFM), these fibrils exhibited a similar level of
HIV-enhancing potency as in vitro SEVI. This finding lends
support to the clinical significance of SEVI.
Currently, the mechanism and structural basis of SEVI is
poorly understood. Solution NMR studies indicated that
monomeric PAP248–286 is disordered in the soluble state
(17) and assumes a highly helical structure in trifluoroetha-
nol (TFE) solution (18). Mu¨nch et al. (3) found that the abil-
ity to enhance HIV infection was imparted only after
PAP248–286 assembles into SEVI fibrils. These fibrils are
presumably constructed by PAP248–286 molecules in
cross-b structure, because they exhibit typical 4.7 and
10.6 A˚ x-ray diffraction rings and show enhanced fluores-
cence signals in thioflavin T (ThT) assay (3). But fibrilliza-
tion is not the only requirement to acquire HIV-enhancing
ability for PAP248–286. Roan et al. (19) showed that mutant
PAP248–286 with positively charged residues replaced byhttp://dx.doi.org/10.1016/j.bpj.2015.03.034
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infection. To probe the fibril cores, French et al. studied the
SEVI by hydrogen-deuterium exchange mass spectrometry
and protease digestion assay. Their results indicate that the
first 7 residues at the N-terminal region are exposed to sol-
vent and flexible, and from residue 14 on the peptide is well
protected and forms the fibril core (20). Moreover, they
found that the N-terminus truncated version of PAP248–
286D1–8 and PAP248–286D1–13 fibrillize even at acidic
environments (20). Taken together, these findings suggest
that cationic charges of wild-type PAP248–286 and fibrillar
supramolecular structure are both essential for SEVI’s abil-
ity to promote HIV infectivity. However, little is known at
the molecular level about its mechanism, which may help
explain apparent conflicting observations about the effect
of SEVI on HIV infection. For example, current evidence
implies heterogeneous HIV-enhancing potency of SEVI in
semen. Specifically, although the level of PAP248–286 in
semen correlates somewhat with HIV-enhancing activity
of pooled semen (4), a strong donor dependence of HIV-
enhancing potency was observed when tested with individ-
ual semen samples (4,16,21).
To our knowledge, we present the first report that the
HIV-enhancing potency of SEVI is morphology dependent.
With TEM, we identified fibrils of two distinct morphol-
ogies, thin (diameter ~3–4 nm) and thick fibrils (diameter
~7–8 nm). They can be formed in two typical in vitro con-
ditions (3,5). In PBS buffer, both thin and thick fibrils are
present with comparable population after 7 days incubation,
whereas most of SEVI are thick fibrils in buffer containing
25 mM sodium bicarbonate and 40 mM sodium phosphate,
pH ¼ 7.7 (NaBiCarb buffer). In addition, although thick fi-
brils formed in both buffers appear similar under TEM, our
solid-state NMR (ssNMR) results showed their structures
actually differ completely at molecular level. In agreement
with ssNMR, fluorescence measurements suggested that
the assembly of PAP248–286 molecules follows two
distinctive pathways in these two conditions, resulting in a
tight molecular packing of SEVI in PBS buffer and a looser
tertiary/quaternary structured SEVI in NaBiCarb buffer.
Most intriguingly, cell-based infectivity tests showed that
the fibrils formed in NaBiCarb buffer exhibit significantly
higher potency to promote HIV infection than those formed
in PBS buffer. Furthermore, we found that SEVI fibrils
exhibit different long-time stability. Although fibrils formed
in NaBiCarb are stable over time, fibrils in PBS keep
evolving as time goes by, and most of the thick fibrils
initially formed get converted into thin fibrils. It suggests
that thin fibrils in PBS are thermodynamically more stable
compared to their thick peers in the solution. Combined,
our data identify a previously unknown structural basis for
the mechanism of SEVI fibrils to enhance HIV infection,
which could possibly lead to the observed heterogeneous
HIV-enhancing potency of SEVI in SP and donor-dependent
HIV-enhancing efficacy of semen (4,21).MATERIALS AND METHODS
Materials
ThT was purchased from Fisher Scientific (Pittsburgh, PA). High purity
(>98%) PAP248–286 peptides (sequence GIHKQKEKSRLQGGVLV
NEILNHMKRATQIPSYKKLIMY) were purchased commercially pro-
duced via solid phase peptide synthesis (EZBiolab, Carmel, IN). Isotope-
labeled PAP248–286 peptide was synthesized by incorporating 13C
uniformly labeled residues at G14, V15, L16, and A27 (underscored resi-
dues in the sequence).Preparation of SEVI fibrils
All SEVI fibril samples for TEM, ssNMR, and infectivity studies were pre-
pared by dissolving fresh synthetic PAP248–286 peptide in PBS or NaBi-
Carb buffer at 5 mg/ml concentration and incubating the clear solution at
37C while shaking at 1400 rpm for a week, as described previously in
the literature (3,5).TEM characterization
All images were acquired on a JEOLTEM-1011 (Peabody, MA) operated at
80 kV using carbon-coated grids (Ted Pella (Redding, CA) ultrathin carbon
(thickness <3nm) on holey carbon support, product No. 1824). Images
were taken with gain set to 1 with 400 ms exposure time, 5 integrations
and 1024  1024 pixels. To prepare TEM samples, a 5 mL droplet of the
sample was deposited on a carbon film-coated grid. After 5 min, the excess
volume was carefully wicked off. Immediately, 5 mL of 3% uranyl acetate
solution was applied briefly and then washed twice with 5 mL distilled de-
ionized water. Five different batches of samples were repeated for each
buffer condition and six TEM samples were analyzed for each sample to
confirm the reproducibility of the observations.SsNMR measurements
SEVI fibrils were prepared with peptide uniformly 13C labeled at G14,
V15, L16, and A27 as described previously. Fibrils were pelleted down
at the end of the 7 days incubation period on a tabletop centrifuge for
1 h. The hydrated pellets at the bottom of centrifuge tubes were then
packed into 3.2 mm thin-wall magic-angle spinning (MAS) rotors for
NMR experiments. SsNMR spectra were acquired on a 600 MHz Bruker
spectrometer (Billerica, MA) at National High Magnetic Field Laboratory
(NHMFL) and a 600 MHz Agilent spectrometer with 3.2 mm low elec-
tric-field MAS probes. Sample temperature was maintained at ~10C
with a stream of cooled gas via variable temperature. The 2D 13C-13C
correlation spectra were acquired with 25 and 100 ms of dipolar-assisted
rotational resonance (DARR) mixing (22) at 13.5 kHz MAS. The ac-
quired spectra were analyzed with NMRPipe (23) and plotted in
SPARKY 3 (T.D. Goddard and D.G. Kneller, University of California,
San Francisco, CA).Fluorescence characterization
ThT assay
Fresh PAP248–286 peptide was dissolved at 5 mg/ml. Samples were then
incubated at 37C with constant shaking at 1400 rpm. For fluorescence
measurements during incubation, 10 mL peptide solution was pipetted out
and diluted to 0.2 mg/ml in a 240 mL quartz cuvette with 25 mMol ThT
for ThT binding assay. The ThT fluorescence was measured using a Jasco
J-810 spectropolarimeter (Easton, MD) with a fluorescence attachment.
Emission spectra were recorded between 400–600 nm at 37C withBiophysical Journal 108(8) 2028–2037
2030 Qiao et al.excitation at 410 nm (24–26). The excitation and emission bandwidths were
2 and 3 nm, respectively, and two scans were collected for each spectrum.
Tyrosine fluorescence
Tyrosine fluorescence was measured immediately following ThT fluores-
cence using the same batch of solutions. Emission spectra were recorded
from 270 to 370 nm at 37C with excitation at 275 nm.Cell lines and viruses
The human cell lines TZM-bl (Dr. John C. Kappes, Dr. Xiaoyun Wu, and
Tranzyme, Research Triangle Park, NC), PM1 (Dr. Marvin Reitz) were ac-
quired from the AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH. TZM-bl cells express HIV-1 coreceptors CD4,
CCR5, and CXCR4 as well as an HIV-1 tat luciferase reporter construct
for quantifying HIV infection. TZM-bl cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (4.5 g/L glucose) containing penicillin,
streptomycin, and 10% (v/v) fetal bovine serum (FBS). PM1 cells are a pro-
myelocytic cell line that also expresses HIV-1 coreceptors, and can propa-
gate HIV-1 virions following exposure to infectious virus. PM1 cells were
maintained in RPMI 1640 supplemented with penicillin, streptomycin,
10 mM HEPES, and 20% FBS. HIV-1 BaL, an R5 strain, was acquired
from the NIH AIDS Research and Reference Reagent Program (Dr. Jay
Levy), and stocks were prepared via propagation in PM1 cells for 5 days.
Cell supernatants were clarified by centrifugation followed by filtration
through a 0.45 mm syringe filter, and stored at 80C in aliquots to be
used as virus stocks. Quantification of viral stocks was performed using
an HIV-1 p24 enzyme-linked immunosorbent assay (ELISA) kit (Perkin
Elmer, Waltham, MA). Viral titer was determined by infecting PM1 and
TZM-bl cells with serial dilutions of viral stock, and identifying the dilution
that resulted in infection of 50% of the culture wells (TCID50/mL).Antiviral and cytotoxicity assays
To determine which fibril arrangement may impart greater effects on HIV
infection, we used the well characterized TZM-bl reporter assay (12,27–
29). The TZM-bl HIV target cells were plated at 6000/well in 96-well
dishes and left to incubate overnight at 37C/5% CO2. The next day, main-
tenance media was aspirated and replaced with 50 mL of serum-free
DMEM containing either of vehicle (PBS or NaBiCarb buffer), soluble
PAP248–286 peptide, SEVI fibrils prepared in PBS, or SEVI fibrils
prepared in NaBiCarb buffer. Peptides were administered at 8.75–
70 mg/mL (twofold serial dilutions), because 35 mg/mL has been shown
to be physiological (3). After 15 min, HIV-1 BaL was diluted in
DMEM/20% FBS and administered to the pretreated cells (50 mL/well)
at a final concentration of 60 TCID50/0.1 mL (MOI ¼ 0.01) for virus,
and DMEM/10% FBS for culture media. Infections were carried out for
24 h at 37C/5% CO2, after which cells were lysed and processed for
luciferase assay (Bright Glo, Promega, Madison, WI). Relative luciferase
units were acquired using an LMax luminometer (Molecular Devices,
Sunnyvale, CA) with a 5 s integration time per well. Statistical analyses
were performed using GraphPad Prism 5 (GraphPad Software, Inc., La
Jolla, CA). Viral enhancement assays of PAP248–286 at different concen-
trations were analyzed by two-way analysis of variance with Bonferroni
posttests to compare luciferase levels from each fibril preparation versus
soluble PAP248–286 peptide or to compare SEVI formed in NaBiCarb
versus SEVI formed in PBS.
TZM-bl assay findings were confirmed using PM1 cells, which can host
and propagate HIV without the use of adjuvants such as DEAE-dextran or
polybrene that are often required for infecting primary peripheral blood
cells in vitro. PM1 cells (1.5  105) were incubated with 35 mg/mL soluble
PAP248–286, SEVI fibrils formed in PBS, or in NaBiCarb, or plain PBS
(volume-matched control) for 10 min before infection with HIV-1 BaL
(150 TCID50/0.1 mL, MOI ¼ 0.001) for 1 h. Cells were then washed to re-Biophysical Journal 108(8) 2028–2037move excess virus, resuspended in growth media containing the appro-
priate treatment, and left to incubate for 2 days. Propagated HIV was
measured by p24 ELISA of collected cell supernatants, and normalized
to the number of live PM1 cells present at the collection time. Cell viability
was monitored by trypan blue exclusion. Paired t-tests were used to directly
compare levels of propagated HIV between each SEVI preparation and sol-
uble PAP248–286, or to compare SEVI formed in NaBiCarb versus SEVI
formed in PBS.RESULTS
Coexistence of thin and thick fibrils identified
by TEM
Freshly synthesized PAP248–286 peptide was dissolved at
5 mg/ml concentration in PBS and NaBiCarb buffers,
respectively. No preexisting fibrils were present in the
freshly dissolved solution as inspected by TEM. The clear
transparent solutions were then incubated at 37C while
shaking at 1400 rpm for 7 days, as described previously
(3,5). During this time, NaBiCarb solution became turbid
after a day, whereas PBS solution became cloudy after
several days (R3 days). Fibrils started to appear in both so-
lutions, as images taken after 3 days incubation shown in
Fig. 1, A and D. After a week of incubation, both solutions
became opaque. At this point, both thin fibrils and thick fi-
brils were present. Fig. 1, B and E, show images of thin fi-
brils in PBS and NaBiCarb buffers, respectively. Their
diameters are around 3–4 nm. Images of thick fibrils in
PBS and NaBiCarb buffers are shown in Fig. 1, C and F,
with diameters around 7–8 nm. The population of thin fibrils
is slightly more than that of thick fibrils in PBS buffer in
TEM. This agrees with the presence of two distinct sets of
resonances for each carbon site in our NMR spectrum taken
immediately after 7 days incubation, see Fig. 3 A. This indi-
cates that thin and thick fibrils consist of molecules in
distinct conformations. In contrast, thin fibrils are rather
rare in NaBiCarb buffer and only present in the less turbid
top layer of the solution, as shown in the Supporting Mate-
rial (Fig. S1). We estimate the population of thin fibrils is
~10% of thick fibrils in NaBiCarb. Two scenarios are
possible to explain this observation. First, thin fibrils in Na-
BiCarb buffer consist of molecules in different conforma-
tion with less density, a different species than the more
populated thick fibrils. Alternatively, these thin fibrils are
in fact the precursory form of thick fibrils in NaBiCarb
buffer, they proceed to further associate together into heav-
ier form and precipitate to the bottom. The latter seems to be
consistent with our NMR data, because a unique set of sig-
nals for each carbon site appear in ssNMR spectrum, see
Fig. 3 B.
Furthermore, SEVI fibrils formed in NaBiCarb buffer
appear stable and do not change their morphology beyond
the initial 7 days incubation, as shown in Fig. S2, C and D.
In contrast, fibrils in PBS buffer keep evolving after the
initial 7 days incubation, even when left in quiescent state
FIGURE 1 Negative-stained TEM images of
SEVI fibrils. (A and D) Short fibrils after 3 days in-
cubation in PBS and NaBiCarb buffer, respectively.
(B and E) Thin fibrils with diameters around 3–
4 nm in PBS buffer and NaBiCarb buffer after
7 days incubation, respectively. (C and F) Thick fi-
brils with diameters around 7–8 nm in PBS buffer
and NaBiCarb buffer after 7 days incubation,
respectively. A bundle of thin fibrils are also pre-
sent in the center of (F).
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buffers gradually grew longer without increasing their
diameter, as shown in Fig. S1, A and B. This evolution in
morphology seems to be accompanied with structural vari-
ation at molecular level (see Fig. 3) by NMR spectra ac-
quired 1 year after the fibrils were prepared by 7 days
incubation. To confirm the observed changes in NMR
spectra, we opened the NMR rotor that contains SEVI fi-
brils formed in PBS buffer a year ago. The fibrils were
briefly resuspended in PBS buffer and their TEM images
are shown in Fig. 2. Most of the thick fibrils disappeared
and a majority of the fibrils were bundled long and thin fi-
brils, consistent with changes manifested in our NMR
spectra.Polymorphism of SEVI at molecular level by
ssNMR
SsNMR measurements were performed on SEVI fibrils
formed in PBS and NaBiCarb buffers, respectively, to probe
their underlying molecular structures at site-specific resolu-
tion. PAP248–286 peptide used for the NMR fibril samples
was uniformly 13C labeled at positions G14, V15, L16, and
A27, as explained in the Methods section. The labeling po-
sitions were chosen to sample regions with different fibrilli-
zation propensities (30), where residues 14–16 were
expected to be the beginning region of fibrillar core (20),
and A27 was at the region with low fibrillization propensity
according to theoretical predictions.FIGURE 2 Negative-stained TEM images of
SEVI fibrils formed in PBS buffer 1 year after its
7 days incubation. Fibrils were retrieved from the
NMR rotor and resuspended briefly in PBS buffers
to prepare TEM samples. As shown in (A) and (B),
most fibrils are long straight bundled thin fibrils.
(C) and (D) show bundled thin fibrils at higher
magnification.
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in PBS and NaBiCarb buffers are shown on the left and right
in Fig. 3, respectively. Spectra at the top row of Fig. 3 were
acquired immediately after the 7 days incubation process,
and spectra at the bottom row were acquired 1 year after
samples packed into NMR rotors. Consistent with the mixed
morphologies in TEM, there are two distinct sets of reso-
nances (labeled as A and B) for each carbon site in Fig. 3
A for fibrils prepared in PBS immediately after 7 days incu-
bation. Both exhibit very sharp signals with line width ~0.8–
1.2 ppm. Fibrils prepared in NaBiCarb buffer show a
slightly broader signal with linewidth ~1.5 ppm in Fig. 3
B. Representative one-dimensional slices at 50.5 and
49.18 ppm for Ala Ca-Cb crosspeaks are shown in Fig. 3,
A and B. The broader linewidth in Fig. 3 B suggests mole-
cules in fibrils formed in NaBiCarb buffer are less ordered
than those in PBS buffers. Nonetheless, the linewidth of
both samples are comparable to those with defined order,
such as the amyloid fibrils formed by Ab140 peptide inFIGURE 3 2D 13C-13C correlation NMR spectra of SEVI fibrils. (A) and (B) w
year after the samples were packed into NMR rotors. (A) and (C) are spectra for S
spectra for fibrils formed in NaBiCarb buffer with 100 and 25 ms DARR mixing,
blue for two different sets of signals. Assignments of interresidue crosspeaks a
extracted at designated positions. To see this figure in color, go online.
Biophysical Journal 108(8) 2028–2037Alzheimer’s disease (31–36). These data indicate that
SEVI fibrils of all morphologies are constructed by well-or-
dered molecular structure in both conditions. The only
exception is that G14 in set B in Fig. 3, A and B. The Ca
signal spreads along the diagonal direction over 4 ppm
range, from ~42.6 to 38 ppm, suggesting rather disordered
conformations for this residue.
With sharp linewidth, all signals in NMR spectra are as-
signed in both spectra. The assignments are listed in Tables
S1 and S2. In Fig. 3 A, each labeled carbon site for SEVI in
PBS buffer exhibits two sets of signals A and B. This agrees
with the heavy mixture of thick and thin fibrils in our TEM
observations in PBS buffer. It reveals that SEVI fibrils of
different morphologies actually consist of molecules in
two different conformations. Furthermore, the population
ratio of fibrils of different thickness can be roughly esti-
mated by the crosspeak intensity between set A and B,
which is ~3:2, consistent with the slight more favorable pop-
ulation of thin fibrils in PBS buffer under TEM.ere acquired immediately after 7 days incubation, and (C) and (D) acquired 1
EVI fibrils formed in PBS buffer with 100 ms DARRmixing. (B) and (D) are
respectively. Assignments of intraresidue crosspeaks are colored in red and
re colored in green and highlighted by circles. One-dimensional slices are
Morphology-Dependent SEVI Potency 2033On the other hand, only one set of signals is present for
nearly all 13C-labeled sites for SEVI fibrils in NaBiCarb
buffer, as shown in Fig. 3 B. The unique set of NMR reso-
nances in Fig. 3 B proves that there is only one structure
in NaBiCarb buffer, and suggests that thin fibrils are prob-
ably precursory assembly for thicker fibrils. The only excep-
tion is A27, where a minor Ca-Cb crosspeak is present. For
A27, the intensity ratio for the strong and weak Ca-Cb
crosspeaks is ~2.14, suggesting A27 adopts two different
and defined conformations in fibrils.
According to the well-established correlation between
secondary structure and NMR signal position (chemical
shift) (37,38), signals in Fig. 3 indicate that nearly all
labeled sites in these fibrils are in b-strand conformation.
Usually secondary shifts are calculated by subtracting
random coil values from observed chemical shifts of C0,
Ca, and Cb for secondary structure prediction. The second-
ary shift analysis of corresponding residues is plotted in
Figs. S3–S5. This agrees well with the hydrogen-deuterium
exchange results that the fibrillar core extends from residue
G14 to its C-terminus in the peptide (20). In addition,
despite the similar appearance in TEM images for thick fi-
brils in both buffers, the differences in NMR chemical shifts
for C0, Ca, and Cb of all residues are generally larger than
1.5 ppm, which suggests that thick fibrils in different buffers
actually consist of molecules in distinct conformations.
To further test the evolution of fibril morphology
observed in TEM, we took NMR spectra of both samples
1 year after the samples were prepared. During this 1
year, NMR samples were stored at quiescent condition at
room temperature. No changes were identified in NMR
spectra for SEVI fibrils prepared in NaBiCarb buffers. To
better differentiate inter and intraresidue crosspeaks, a
25 ms DARR spectrum for SEVI fibrils in NaBiCarb sample
was also acquired at the same time and is shown in Fig. 3 D.
The strong signals in Fig. 3 D agree well with sites at one-
bond distance away and their positions are identical to those
in Fig. 3 B, supporting our TEM observation with no struc-
tural variation over the extended time period. Two interresi-
due crosspeaks between L16 and V15 are present in Fig. 3 B
but absent due to shorter mixing time in Fig. 3 D, as high-
lighted by circles in Fig. 3 B.
On the other hand, spectra acquired after 1 year for SEVI
samples in PBS buffer indicate structural evolution at mo-
lecular level over a long time. 100 ms and 25 ms DARR
mixing spectra acquired 1 year after the sample was packed
are shown in Figs. 3 C and S6. First of all, resonances cor-
responding to B set signals (thick fibrils) exhibit much atten-
uated intensity compared to their counterparts in Fig. 3 A.
For example, all intraresidue crosspeaks for V15B are
much weaker, and those for L16B and A27B are almost
invisible. On the other hand, most of the resonances corre-
sponding to A set signals (thin fibrils) remain unchanged
and strong with the exceptions for crosspeaks involving
Cb of L16A. Although signals at positions correspondingto L16A Cb in Fig. 3 A remain still visible with attenuated
intensity in Fig. 3 C, new dominant signals appear at posi-
tions near the original positions of Cb of L16A and L16B
in Fig. 3 A. This new resonance frequency is almost iden-
tical to the old Ca of G14A, and shifts toward higher fre-
quency in comparison with L16A Cb in Fig. 3 A. We
associate them with L16 Cb because they ((45, 53) and
(28, 45) ppm) exhibit strong resonances in 25 ms mixing
spectrum, which suggests they are intraresidue crosspeaks
involving L16A Cb instead of interresidue signals involving
G14 Ca. This indicates that L16A adopts a more b-sheet-
like conformation. Combined, the attenuated resonances
for B set of signals and largely conserved A set of signals
corroborate very well with the concomitant decreasing pop-
ulation of thick fibrils and dominant elongated thin fibrils of
the sample in TEM images. It also confirms our assignments
to associate A set of signals with thin fibrils and B with thick
fibrils in PBS. It suggests that secondary structure for thin
fibrils is largely retained during their elongation, with a
more b-sheet-like state associated with L16. In addition,
all interresidue crosspeaks for A set of signals in Fig. 3 A
are still present in Fig. 3 C but with much weaker intensity,
and the interresidue signals for B set of signals in Fig. 3 A
are completely gone. This indicates accompanied tertiary
and quaternary structure variations for fibrils formed in
PBS buffer over time.Assembly kinetics tracked by fluorescence
To assess the kinetics and conformational transitions accom-
panying assembly, we performed fluorescence characteriza-
tion. We found that PAP248–286 in PBS and NaBiCarb
buffer follow distinct fibrillization pathways. Fig. 4 A shows
fibrillization kinetics monitored by ThT assay over 115 h,
starting with PAP248–286 peptide freshly dissolved in
PBS and NaBiCarb buffers separately. For NaBiCarb buffer,
the time dependence of ThT fluorescence can be described
by a single exponential curve y ¼ A0et=t, with a best fit
time constant of t ¼ 3.33 h. But for fibrillization in PBS
buffer, the increase of ThT fluorescence appears to be
much slower than 115 h. The data points within 115 h could
not be captured by a single exponential with t ¼ 336 h, as
shown in Fig. 4 A. This agrees with our TEM and NMR
observation that both the fibril morphology and molecular
conformation keeps evolving over the time beyond the
7 days incubation period. In addition, ThT fluorescence in-
tensity quickly reaches a significantly higher level for
PAP248–286 fibrils in the NaBiCarb buffer as compared
to those in PBS. This agrees with the observation of highly
populated short fibrils in NaBiCarb buffer just in 3 days in-
cubation, but much fewer fibrils in PBS buffer. Variations of
ThT fluorescence intensity in the presence of different am-
yloid fibrils have been detected before and explained in
terms of distinct ThT-fibril binding constants and stoichiom-
etry, as well as structural differences among the fibrilsBiophysical Journal 108(8) 2028–2037
FIGURE 4 Fibrillization kinetics monitored by fluorescence. Signals for samples in PBS and NaBiCarb buffer are labeled by circles and squares, and their
best fit with single exponential curves are represented by solid and dashed lines, respectively. (A) ThT fluorescence assay during 115 h of incubation. The fit to
PBS buffer is poor due to the continuing increase of the signal. (B) Tyrosine fluorescence intensity and (C) maximum wavelength lmax are presented. To see
this figure in color, go online.
2034 Qiao et al.(25,26). Although data in Fig. 4 A cannot distinguish these
possibilities, they are consistent with distinct structures of
SEVI fibrils in two buffers at molecular identified in our
NMR spectra.
In addition, there are two tyrosines (Tyr) at the C-termi-
nus (residues 33 and 39, bolded in the sequence shown in
the Methods section) of PAP248–286. Tyr fluorescence
was used to probe the changes of local microenvironments,
such as solvent accessibility (39). As shown in Fig. 4 B, Tyr
fluorescence intensity significantly decreases during fibrillo-
genesis in NaBiCarb, whereas the change for sample in PBS
buffer is much weaker and six times slower. Furthermore, fi-
brillization of PAP248–286 in NaBiCarb buffer is accompa-
nied with a 3 nm red shift, although no spectral shift occurs
in PBS, as shown in Fig. 4 C. The red shift over time in Na-
BiCarb can be described by a single exponential curve with
t ¼ 27.5 h. The time constant of Tyr fluorescence intensity
change in NaBiCarb is t¼ 30.3 h, similar to that of its spec-
tral red shift. It indicates that at least the C-terminal part of
PAP248–286 molecules assumes a loose, more solvent
accessible tertiary/quaternary structure in SEVI formed in
NaBiCarb buffer, resulting in solvent relaxation and solvent
quenching (39). In contrast, the same region in the mixed fi-
brils in PBS buffer forms a more compact and solvent-pro-
tected structure. These data are consistent with our NMR
data that the structures of SEVI in two buffers are different.
If we assume the fibrils with loose packing in NaBiCarb
buffer will lead to a more disordered molecular structure
(inhomogeneous broadening for NMR signals), it also
agrees with the slightly broader NMR signals for SEVI in
NaBiCarb buffer as observed in Fig. 3.Enhancement of HIV infection by PAP248–286
fibrils
HIV infection assays on fibrils formed in PBS and NaBiCarb
buffers were done immediately after 7 days incubation to
determine if their differences in structure affect their ability
to enhance HIV infection. The HIV reporter cell line
TZM-bl produces luciferase proportional to HIV-1 inoc-Biophysical Journal 108(8) 2028–2037ulum, and luciferase levels were not altered by addition of
PBS or NaBiCarb buffer, as shown in Fig. 5 A. Soluble
PAP248–286 peptide did not impact HIV, although both
fibril types promoted increased HIV infection at 10–
35 mg/ml, which is reported to be physiological (3), as
shown in Fig. 5 B. SEVI formed in NaBiCarb exhibited
greater potency than fibrils formed in PBS buffer. To confirm
these findings, fibrils were compared to soluble PAP248–
286 and PBS buffer control in PM1 cells, which are capable
of propagating infectious HIV virions upon a brief exposure.
Cells were treated with PBS buffer or 35 mg/ml PAP248–286
10 min before administration of HIV for 1 h. Cells were then
washed off to remove the excess virus and PAP248–286, and
retreated with PBS or PAP248–286. At 2 days postinfection,
cells were counted and assessed for viability; and propa-
gated HIV was measured by p24 ELISA. Using an HIV
MOI ¼ 0.001, only low ng/mL levels of HIV p24 were de-
tected in cultures of PM1 target cells coincubated with PBS
or soluble PAP for 2 days; however, SEVI exposure resulted
in appreciably higher levels of HIV p24 in the cultures, as
shown in Fig. 6 A. The enhancement of HIV infection by
SEVI, though variable among the cell passages used in
four replicate experiments, was remarkable considering
that SEVI-treated HIV-infected PM1 cells did not proliferate
to the levels of infected cells coincubated with PBS buffer or
soluble PAP peptide, Fig. 6 B. When HIV p24 ELISAvalues
were normalized to live cell number at the time of harvest, it
became evident that SEVI formed in NaBiCarb was more
proviral than SEVI formed in PBS, as shown in Fig. 6 C.
Pairwise comparisons of the PAP treatments versus buffer
control showed that SEVI in NaBiCarb enhanced HIV infec-
tion by 900% and was almost twice as potent as SEVI
formed in PBS, as shown in Fig. 6 D.DISCUSSION
Previously, characterizations of SEVI morphology by TEM
(3,5,19,21,40,41) and AFM (20,42) have been reported. To
our knowledge, we present the first report of the structural
characterization at molecular level and prove that the
FIGURE 5 HIV reporter assay reveals functional
differences between PAP peptide and fibrils. (A)
TZM-bl cells were incubated with growth media
alone, or PBS or NaBiCarb buffers volume
matched to 70 mg/mL of each respective SEVI
fibril preparation, and then immediately infected
with HIV-1 BaL (1–4 ng/mL p24; MOI ¼ 0.01–
0.04) for 24 h. (B) TZM-bl cells were treated
with PBS (control), soluble PAP peptide, SEVI fi-
brils prepared in PBS, or in NaBiCarb immediately
before HIV-1 BaL infection (1 ng/mL p24; MOI ¼
0.01) for 24 h. HIV-1 tat-driven luciferase produc-
tion was measured and presented as mean 5 SE,
N ¼ 3. *P < 0.01 versus soluble PAP and P < 0.05 versus SEVI in PBS. **P < 0.001 versus soluble PAP and P < 0.05 versus SEVI in PBS. #P <
0.01 versus soluble PAP. ##P < 0.001 versus soluble PAP. To see this figure in color, go online.
Morphology-Dependent SEVI Potency 2035difference in SEVI fibril structure correlates with their po-
tency to enhance HIV infection.
Our TEM images identified SEVI fibrils with distinct
morphologies, thin and thick fibrils, present in both prepara-
tion methods. Although fibrils of similar diameters in
different buffers appear indistinguishable under TEM,
ssNMR suggested that their structures differ at molecular
level, with an average difference of chemical shift larger
than 1.5 ppm. Furthermore, we showed that thin and thick
fibrils in PBS buffers actually consist of molecules in
different conformation, manifested by their distinct NMR
chemical shifts. In contrast, the much less populated thin fi-
brils in NaBiCarb buffers appear to be an on pathway prod-
uct for the thick fibrils, because only a unique set of NMR
signal for each labeled site was identified. In addition, fibrils
in PBS still evolve after 7 days incubation as our TEM and
NMR results showed, consistent with the continuous
increasing fluorescence in its ThT assay in the first 115 h.
In contrast, the fibrils in NaBiCarb remain unchanged
once formed after 7 days incubation.Although two distinct sets of resonances are present in
spectra of fibrils prepared in PBS buffer, the concomitant
changes of fibril morphology in TEM images help to asso-
ciate them unambiguously with different fibrils. However,
assignments of two resonance signals in Fig. 3 A remain
to be further tested in the future. They are crosspeak at
(33.5, 44) ppm assigned to Cb of V15 in set B and Cb of
L16 in set A, and crosspeak at (44, 60.5) ppm assigned to
Ca of V15 in set B and Cb of L16 in set A. They are the
most reasonable assignments given current knowledge.
These two crosspeaks were only present in Fig. 3 A acquired
immediately after 7 days incubation and disappeared in
spectrum acquired a year later in Fig. 3 C. They indicate
close proximity of V15 in thick fibrils with L16 in thin fi-
brils. This is only possible if two fibrils were actually phys-
ically entangled. Our TEM observation showed that most
fibrils were eventually converted to thin fibrils, which im-
plies continuous disassembly of thick fibrils to rearrange
into thin fibrils. Thus, the possibility for thin and thick fibrils
to be at close proximity cannot be ruled out. FurtherFIGURE 6 Augmented proviral effect of SEVI
formed in NaBiCarb. PM1 cells were exposed to
35 mg/mL soluble PAP peptide, SEVI formed in
PBS, SEVI formed in NaBiCarb, or plain PBS (vol-
ume-matched control) for 10 min and then infected
with HIV-1 BaL, as described in Materials and
Methods. Propagated HIV (ng/mL p24) was
measured by ELISA (A), and normalized to live
cell numbers (B), revealing the amount of HIV
propagated per cell (C). (D) Bars represent % in-
crease in infection compared to the paired buffer
control. Results are presented as mean 5 SE,
N ¼ 4. *P ¼ 0.038 for SEVI in PBS versus PBS-
treated HIV-infected cells in (B). *P ¼ 0.019 for
SEVI-NaBiCarb versus PBS in panel B. *P ¼
0.048 for SEVI in NaBiCarb versus PBS in (C).
*P ¼ 0.017 for SEVI in PBS versus soluble PAP
in (D). **P ¼ 0.011 for SEVI in NaBiCarb versus
soluble PAP and P ¼ 0.028 versus SEVI in PBS
in (D). To see this figure in color, go online.
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2036 Qiao et al.experiments would be necessary to consolidate this indica-
tion, for example, samples prepared with a mixture of pep-
tide 50% labeled at V15 and the other half labeled at L16.
However, we note that the uncertainty of these assignments
do not impact on our conclusion of this work that there are
two species of fibrils with distinct morphology and viral
enhancing potency. In addition, more thorough characteriza-
tions at a different times are needed to delineate the detailed
time dependence of SEVI evolution in PBS.
Previously, solution NMR measurements indicated that
PAP248–286 assumes disordered structure in micelles (17)
and exhibits helical tendency in TFE solution (18). We
note that their results were obtained with soluble samples,
not fibrils. Therefore, their structural models are for
PAP248–286 in the unfibrillized state, not directly related
to SEVI fibrils or the HIV-enhancing effect. Earlier results
also showed the ability of PAP248–286 to induce lipid ag-
gregation and fusion (43), hence these disordered/helical
conformations of PAP248–286 may be related to such
behaviors.
In a recent report by Usmani et al., (16) endogenous SEVI
fibrils were found in human semen. The thick fibrils we
observed have a similar diameter to their AFM characteriza-
tion (around 5–7 nm). However, the limited magnification in
their TEM images make it difficult to conclude if thinner fi-
brils are also present in semen. Yet we cannot exclude this
possibility, especially since abundant fibrils appear in their
TEM images to bundle up parallel to each other, exhibiting
a typical appearance that we observed for thin fibrils formed
in vitro.
Our cell-based infectivity tests identify a previously un-
known correlation between the morphology of SEVI fibrils
and their efficacy to promote HIV infection (Figs. 5 and 6).
Both infection assays largely depend on how many HIV par-
ticles can enter host cells during the first hours of exposure.
It can therefore be surmised that thick SEVI fibrils in
NaBiCarb buffer are significantly more potent to enhance
viral fusion compared to those prepared in the PBS buffer.
We note that the in vivo concentration of PAP248–286 has
been estimated to be as high as 35 mg/ml (3), whereas our
infectivity assays showed the maximum potency. This is
consistent with other studies that revealed the potency of
semen-enhanced infection to correlate with SEVI levels in
the low mg/mL range (4). At twice the concentration
(70 mg/ml), our assays revealed decreased luciferase values,
which is not surprising considering that enhanced SEVI-
mediated viral fusion could stress the target cells beyond
their capacity for synthesizing luciferase, as demonstrated
by Kim et al (4). Alternatively, this finding might be related
to the observed aggregation of fibrils at high peptide con-
centration that could lead to reduced exposed active sites
per fibril strand to promote binding with virus particle;
and illustrate a fine line between bridging HIV to target cells
and blocking HIV from target cells. If this were true, this
could be another factor contributing to the complexities ofBiophysical Journal 108(8) 2028–2037studying SEVI-mediated HIV transmission in vivo. More
studies are needed to determine the composition of fresh
semen samples with respect to varying concentrations of
thick, thin, and aggregated SEVI fibrils.CONCLUSION
To our knowledge, we presented here the first report for the
morphology-dependent potency to enhance HIV infection of
SEVI fibrils by TEM, ssNMR, and fluorescence measure-
ments. Our spectroscopy data consistently show that
PAP248–286 molecules form amyloid fibrils of distinct
morphologies that consist of molecules in different confor-
mations assembled along different pathways. Furthermore,
these distinct SEVI fibrils exert different efficacies of
HIV-enhancement. Our results suggest that the difference
in reported potencies of SEVI fibrils to promote HIV infec-
tion may be due to the different SEVI fibrils present in test
samples (15,16), which could explain the donor-dependent
HIV-enhancing potency of semen (16). Furthermore, we
also showed that fibrils formed in PBS buffer undergo
morphological variations beyond 7 days incubation. Most
assemblies will eventually be converted to long and thin fi-
brils. They have similar secondary structure to the thin fi-
brils produced immediately after 7 days incubation, and
exhibit different overall folding.SUPPORTING MATERIAL
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